Gufic Biosciences Limited — Meropenem Exporter Profile
Indian Pharmaceutical Exporter · #4 for Meropenem · $750.0K export value · DGFT Verified
Gufic Biosciences Limited is the #4 Indian exporter of Meropenem with $750.0K in export value and 15 verified shipments. Gufic Biosciences Limited holds a 0.3% market share in Meropenem exports across 4 countries. The company exports 5 pharmaceutical products worth $12.6M across 4 therapeutic categories.
Gufic Biosciences Limited — Meropenem Export Profile: Buyers & Destinations
Where Does Gufic Biosciences Limited Export Meropenem?
| Country | Value | Shipments | Share |
|---|---|---|---|
| SRI LANKA | $400.0K | 9 | 61.5% |
| CUBA | $150.0K | 3 | 23.1% |
| COSTA RICA | $100.0K | 2 | 15.4% |
| LEBANON | $2 | 1 | 0.0% |
Gufic Biosciences Limited exports Meropenem to 4 countries. The largest destination is SRI LANKA accounting for 61.5% of Gufic Biosciences Limited's Meropenem shipments, followed by CUBA (23.1%) and COSTA RICA (15.4%). These destinations reflect Gufic Biosciences Limited's established distribution network and regulatory approvals in key markets.
Who Are the Top Buyers of Meropenem from Gufic Biosciences Limited?
| Buyer | Country | Value | Orders |
|---|---|---|---|
| SEYLAN BANK PLC, | SRI LANKA | $200.0K | 4 |
| NATIONS TRUST BANK PLC, | SRI LANKA | $200.0K | 4 |
| MEDICUBA, | CUBA | $100.0K | 2 |
| TO THE ORDER OF | COSTA RICA | $50.0K | 2 |
| MEDICUBA | CUBA | $50.0K | 1 |
| SLIM PHARMACEUTICALS PVT LTD | SRI LANKA | $48 | 1 |
Gufic Biosciences Limited supplies Meropenem to 6 buyers globally. The largest buyer is SEYLAN BANK PLC, (SRI LANKA), followed by NATIONS TRUST BANK PLC, (SRI LANKA) and MEDICUBA, (CUBA). These buyers represent pharmaceutical distributors, hospital groups, and government procurement agencies in their respective markets.
What Is India's Total Meropenem Export Value and How Much Does Gufic Biosciences Limited Contribute?
India exported $80.5M worth of Meropenem through 3,658 shipments from 401 suppliers to 134 countries, serving 966 buyers globally. Gufic Biosciences Limited contributes $750.0K to this total, accounting for 0.3% of India's Meropenem exports. Gufic Biosciences Limited ships Meropenem to 4 countries through 6 buyers.
What Is the Average Shipment Value for Gufic Biosciences Limited's Meropenem Exports?
Gufic Biosciences Limited's average Meropenem shipment value is $50.0K per consignment, based on 15 shipments totaling $750.0K. The largest destination is SRI LANKA (61.5% of Gufic Biosciences Limited's Meropenem exports).
How Does Gufic Biosciences Limited Compare to Other Indian Meropenem Exporters?
Gufic Biosciences Limited ranks #4 among 401 Indian Meropenem exporters with a 0.3% market share. The top 3 exporters are VENUS REMEDIES LIMITED ($40.0M), EUGIA PHARMA SPECIALITIES LIMITED ($17.1M), SUN PHARMACEUTICAL INDUSTRIES LIMITED ($10.3M). Gufic Biosciences Limited processed 15 shipments to 4 destination countries.
What Meropenem Formulations Does Gufic Biosciences Limited Export?
| Product Description / Formulation | Value | Shipments |
|---|---|---|
| MEROFIC 1G INJ (MEROPENEM INJECTION 1G) | $200.0K | 4 |
| MEROFIC 1G (Meropenem Injection 1g) | $100.0K | 2 |
| MEROFIC 1G Meropenem Injection 1g (BATCH | $100.0K | 2 |
| MEROPENEM 1G Fx1 VIAL 20ML) (MEROPENEM F | $50.0K | 1 |
| MEROPENEM 1G Fx1 VIAL 20ML (MEROPENEM FO | $50.0K | 1 |
| MEROPENEM 1G (MEROPENEM FOR INJECTION US | $50.0K | 1 |
| MEROPENEM MEROPENEM FOR INJECTION USP 1 | $50.0K | 1 |
| MEROPENEM 1G Fx1 VIAL 20ML (100000 vials) | $50.0K | 1 |
| NCV:MEROFIC I gm INJ MEROPENEM FOR INJECTION USP 1 gm 100 VIALS | $48 | 1 |
| NCV Meropenem USP Working standard | $2 | 1 |
Gufic Biosciences Limited exports 10 distinct Meropenem formulations including tablets, capsules, syrups, and combination drugs. The top formulation is MEROFIC 1G INJ (MEROPENEM INJECTION 1G) with 4 shipments worth $200.0K.
How Does Gufic Biosciences Limited Compare to Nearest Meropenem Exporters?
Exporters ranked immediately above and below #4 by export value
| # | Supplier | Export Value | Shipments | Countries | Avg/Shipment |
|---|---|---|---|---|---|
| 11 | M. J. BIOPHARM PRIVATE LIMITED | $1.4M | 45 | 9 | $32.1K |
| 7 | VHB MEDI SCIENCES LIMITED | $800.0K | 16 | 4 | $50.0K |
| 4 | GUFIC BIOSCIENCES LIMITED ★ | $750.0K | 15 | 4 | $50.0K |
| 15 | REMUS PHARMACEUTICALS LIMITED | $691.0K | 19 | 1 | $36.4K |
| 14 | M J BIOPHARM PRIVATE LIMITED | $650.0K | 13 | 6 | $50.0K |
Gufic Biosciences Limited ranks #4 among 401 Indian Meropenem exporters. Average shipment value of $50.0K compared to the market average of $200.8K. The closest competitors by value are M. J. BIOPHARM PRIVATE LIMITED and VHB MEDI SCIENCES LIMITED.
Which Indian Ports Ship Meropenem Exports?
| Port | Shipments | % Share |
|---|---|---|
| DELHI AIR CARGO ACC (INDEL4) | 504 | 13.8% |
| DELHI AIR | 494 | 13.5% |
| SAHAR AIR | 256 | 7.0% |
| SAHAR AIR CARGO ACC (INBOM4) | 246 | 6.7% |
| NHAVA SHEVA SEA (INNSA1) | 233 | 6.4% |
| CMA CGM LOGISTICS PARK ICD (INCPL6) | 198 | 5.4% |
| Delhi Air | 103 | 2.8% |
| DHANNAD ICD (INDHA6) | 94 | 2.6% |
What Other Advanced Antibiotics Products Does Gufic Biosciences Limited Export?
Gufic Biosciences Limited also exports these advanced antibiotics products. Each links to the detailed product page.
Geopolitical & Trade Policy Impact on Gufic Biosciences Limited's Meropenem Exports
The current geopolitical landscape presents both challenges and opportunities for Indian pharmaceutical exporters like Gufic Biosciences. The Israel-Iran conflict has led to increased tensions in the Red Sea, a vital shipping route for Indian exports. Houthi attacks in the region have disrupted maritime logistics, resulting in higher shipping costs and potential delays. These disruptions could impact Gufic's supply chain efficiency and delivery timelines, necessitating strategic adjustments to maintain export commitments.
In the United States, recent tariff policies have introduced uncertainties for pharmaceutical imports. While health products have been exempt from tariffs, there have been threats to impose significant increases to encourage domestic production. Such measures could affect Indian exporters, including Gufic, by altering the competitive landscape and potentially reducing market share in the U.S. (lemonde.fr)
Conversely, U.S.-China trade tensions have opened avenues for Indian pharmaceutical companies to fill gaps left by Chinese suppliers. Gufic could leverage this opportunity to expand its footprint in markets seeking alternative sources for pharmaceutical products.
In the European Union, compliance with the Falsified Medicines Directive (FMD) remains a critical requirement for exporters. The directive mandates stringent serialization and traceability measures to prevent counterfeit medicines from entering the supply chain. Gufic's adherence to these regulations is essential to maintain and grow its presence in the EU market.
Gufic Biosciences Limited — Regulatory Compliance & Quality Standards
Compliance with international regulatory standards is paramount for Indian pharmaceutical exporters. Gufic's Indore facility, which commenced production in October 2024, is designed to meet WHO GMP, EU GMP, ANVISA, MHRA, and USFDA standards. This facility has achieved 30% capacity utilization for FY26 and is on track for EBITDA breakeven. Such compliance not only facilitates market access but also enhances the company's reputation for quality and reliability. (scanx.trade)
However, recent tax-related penalties highlight the importance of robust internal controls and adherence to financial regulations. Gufic's proactive approach in appealing these penalties demonstrates its commitment to regulatory compliance and financial integrity.
About Gufic Biosciences Limited
Gufic Biosciences Limited exports 5 products worth $12.6M. Beyond Meropenem, top products include Vancomycin, Teicoplanin, Strip, Amphotericin. View the complete Gufic Biosciences Limited profile for full portfolio analysis.
Market Intelligence
Latest developments and market context
Detailed market intelligence for Meropenem — including regulatory updates, trade policy changes, and competitive landscape analysis — will be available in an upcoming update. This section will feature AI-researched insights from verified industry sources, government notifications, and market reports.
Official References & Regulatory Resources
- CDSCO India
- Pharmexcil
- IBEF — India Pharma Industry
- Ministry of Commerce — Pharma Exports
- India Trade Statistics (DGFT)
Verify manufacturer licensing and export certifications with the official agencies above.
Research Methodology & Data Transparency
Suresh Sormare
Verified AuthorPharmaceutical Export-Import Analyst & Trade Intelligence Expert
Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.
linkedin.com/in/sureshsormarePrimary Data Source
All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.
Analysis Methodology
- 1.Product Matching: Meropenem shipments identified using fuzzy matching on DGFT product description fields, validated against Indian Pharmacopoeia nomenclature.
- 2.Supplier Identification: Gufic Biosciences Limited matched across shipments using name normalization, accounting for company name formatting variations.
- 3.Statistical Normalization: Shipment values are statistically normalized to ensure accurate market share representation. This removes the impact of unusually large one-off transactions that could distort company rankings.
- 4.Verified Records: This page is backed by 15 individual customs records matching Gufic Biosciences Limited exporting Meropenem, covering 10 formulations to 4 countries via 6 buyers.
Government-Sourced Data
Official DGFT customs records
Transparent Methodology
Calculations fully disclosed above
Global Coverage
Exports to 134+ countries, 966+ buyers
Expert-Reviewed
Analyzed by pharmaceutical trade specialists
Get Meropenem Export Data from Gufic Biosciences Limited
Access shipment-level details, pricing data, buyer connections, and competitive analysis for Gufic Biosciences Limited's Meropenem exports. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.
Gufic Biosciences Limited
Full Company Profile →
5 products · $12.6M total trade · 4 categories
Meropenem Stats
Company Overview
Top Products by Gufic Biosciences Limited
Related Analysis
Need Detailed Export Data?
Access shipment-level records, pricing trends, and buyer contacts for Gufic Biosciences Limited.
Request DemoView Pricing →Data Source
Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Market share calculated relative to total Indian pharmaceutical exports for Meropenem. For current shipment-level data, contact TransData Nexus.